Dermira, Inc. (NASDAQ: DERM) filed an S-1 form with the Securities and Exchange Commission (SEC) for a secondary offering. There were no terms given in this initial filing but the proposed maximum price is estimated at $97.75 million but this is really just a placeholder.
Source: Thinkstock
The underwriters for this offering are Leerink Partners, Cowen, Needham, and Guggenheim.
Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. The management team has extensive experience in product development and commercialization, having served in leadership roles at several leading dermatology companies.
Its strategy is to leverage this experience to in-license, acquire, develop and commercialize products that Dermira believes can be successful in the dermatology marketplace. The company has a portfolio of five product candidates targets significant market opportunities and includes three late-stage product candidates: Cimzia (certolizumab pegol), for the treatment of moderate-to-severe plaque psoriasis; DRM04, for the treatment of hyperhidrosis, or excessive sweating; and DRM01, for the treatment of acne.
The company is currently focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as psoriasis, hyperhidrosis and acne. These diseases impact millions of people worldwide and can have significant, multidimensional effects on patients’ quality of life, including their physical, functional and emotional well-being.
Finally, Dermira currently intends to use the net proceeds from this offering for external research and development expenses associated with the development of Cimzia, DRM04 and DRM01 product candidates, with the balance primarily used to fund internal research and development expenses associated with all of the product candidates, working capital, capital expenditures and other general corporate purposes.
ALSO READ: How The Biggest Biotech IPO Did In Its Debut
Shares of Dermira closed Tuesday up 0.2% at $24.37 on a 52-week trading range of $12.68 to $25.24. The stock has a consensus analyst price target of $24.75.
Essential Tips for Investing: Sponsored
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
